This review summarizes current knowledge on endothelial dysfunction, its biomarkers (NO, endothelin), and potential pharmacological interventions to improve cardiovascular outcomes.
Endothelial dysfunction assessment should not yet change practice; leaves open standardized NO and endothelin evaluation in CVD.
The review describes the current understanding of endothelial dysfunction, methods of its evaluation, and highlights the advantages and disadvantages of various techniques. The role of nitric oxide and endothelin as important markers of endothelial dysfunction is shown, and the methods of their determination in clinical practice are described. The authors conclude that in order to improve the life expectancy and quality of life of patients with cardiovascular diseases, reduce the risk and frequency of complications and mortality rates, it is necessary to study the function of endothelium in more detail and to look for ways of drug correction, taking into account the pathogenetic mechanisms of its formation.
No takes yet. Share an insight, caveat, or question.
Samolyuk et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: